|
|
Article: NEWBIOTICS/ELAN TO DEVELOP COLON CANCER TREATMENT.
- Article from:
- Worldwide Biotech
- Article date:
- March 1, 2001
CopyrightCOPYRIGHT 2001 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NewBiotics Inc. and Elan Corp., plc (NYSE: ELN), have formed a joint venture to develop and commercialize NewBiotics' lead compound, NB1011, to treat cancer in the United States, Canada and Europe. The initial focus of NB1011 will be on treating patients with colorectal cancer who have not responded well to standard chemotherapy.
As part of the agreement, Elan has made an equity investment in NewBiotics and gained the opportunity to negotiate commercialization rights to NB1011 for cancer treatment in the United States, Canada and Europe. In addition, the joint venture will receive certain rights to utilize Elan's NanoCrystal(TM) technology.
"We are ...
Related newspaper, magazine, and journal articles:
|
|
Article: $11 Million Financing for NewBiotics Inc.
PR Newswire;
July 26, 2001 ;
700+ words
... ... investors and partners." About NewBiotics Inc. NewBiotics Inc., of San Diego, is ... resistance, ECTA provides a "Trojan Horse Solution" to this problem ... information, visit www.newbiotics.com. MAKE YOUR OPINION ...
|
|